Products
Peramivir was approved in the United States in 2014 and in the EU in 2018 as a concentrate for the preparation of an infusion solution (U.S.: Rapivab, EU: Alpivab). It has not yet been registered in many countries.
Structure and properties
Peramivir (C15H28N4O4, Mr = 328.4 g/mol) is present in the drug as peramivir trihydrate (- 3 H2O). Unlike other neuraminidase inhibitors such as oseltamivir (Tamiflu), peroral administration is not possible.
Effects
Peramivir (ATC J05AH03) has antiviral properties against influenza viruses. It reduces the duration and severity of illness. The effects are due to inhibition of viral neuraminidase and thus viral replication. Neuraminidase is central on the surface of influenza viruses for the release of newly formed viruses from infected cells and thus for the further spread of infectious viruses in the organism. Peramivir has a long half-life of about 20 hours.
Indications
For the treatment of acute and uncomplicated influenza (flu).
Dosage
According to the SmPC. The drug should be administered as a single dose within two days of the onset of symptoms. It is infused as an intravenous infusion.
Contraindications
Peramivir is contraindicated in the presence of hypersensitivity. For complete precautions, see the drug label.
Interactions
Peramivir does not interact with CYP450, UGT, or P-glycoprotein. Interactions are considered unlikely. It should not be administered concomitantly with an influenza vaccine if it contains live influenza virus.
Adverse effects
The most common possible adverse effects include a decrease in neutrophil count, nausea, and vomiting.
